Glenmark Pharmaceuticals has been granted final approval by the US FDA for Nitroglycerin sublingual tablets USP, 0.3 mg, 0.4 mg, and 0.6 mg, the generic version of Nitrostat sublingual tablets, 0.3 mg, 0.4 mg, and0.6 mg, of Pfizer Inc.

Glenmark's current portfolio consists of 125 products authorized for distribution in the US marketplace and 61 abbreviated new drug applications (ANDAs) pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.


10 Diagnostic Imaging Trends for 2018

Best of 2017 Medical

 

Digital version